viewPressure BioSciences, Inc.

Full interview: Pressure BioSciences CEO sees potential opportunity to enter clinical market after recent customer data

Pressure BioSciences Inc (OTCMKTS:PBIO) CEO Ric Schumacher tells Proactive the medical device company's signature Pressure Cycling Technology (PCT) platform has been highlighted by scientists in China and Australia, which Schumacher says could eventually propel the company into the clinical market space.

The two separate cancer research organizations, who are some of Pressure's largest customers, published findings that showcased PCT’s ability to discover biomarkers associated with cancer in tissue samples preserved from biopsies and highlighted its potential as a diagnostic tool.

Quick facts: Pressure BioSciences, Inc.

Price: 1.8 USD

Market: OTCQB
Market Cap: $6.44 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Pressure BioSciences, Inc. named herein, including the promotion by the Company of Pressure BioSciences, Inc. in any Content on the Site, the...


Salt Lake Potash CEO says project's 'flying along' as it passes 60% completion

  Salt Lake Potash Ltd (ASX:SO4) (LON:SO4) CEO Tony Swiericzuk tells Proactive's Andrew Scott the project's 'flying along' as it passes 60% completion and adds that they're still on schedule to deliver first SOP production in the March quarter of 2021. He says the major vendor...

2 hours, 11 minutes ago

2 min read